TITLE

Iloperidone: Does it have a meaningful place in therapy?

PUB. DATE
February 2011
SOURCE
American Journal of Health-System Pharmacy;2/15/2011, Vol. 68 Issue 4, p297
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
58043457

 

Related Articles

  • Iloperidone: A new drug for the treatment of schizophrenia. Arif, Sally A.; Mitchell, Melissa A. // American Journal of Health-System Pharmacy;2/15/2011, Vol. 68 Issue 4, p301 

    Purpose. The pharmacology, pharmacokinetics, pharmacogenomics, clinical efficacy, and safety and tolerability profile of iloperidone for the treatment of schizophrenia are reviewed. Summary. Iloperidone is an atypical antipsychotic that recently received marketing approval from the Food and Drug...

  • Olanzapine-induced Orthostatic Hypotension. Jana, Amlan Kusum; Praharaj, Samir Kumar; Roy, Nirmalya // Clinical Psychopharmacology & Neuroscience;Apr2015, Vol. 13 Issue 1, p113 

    Olanzapine is an atypical antipsychotic which is efficacious in the treatment of schizophrenia. The adverse effect profile for olanzapine is benign except for higher rates of metabolic events. Orthostatic hypotension is less commonly reported with olanzapine as compared to first-generation and...

  • Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. Graff-Guerrero, Ariel; Rajji, Tarek K.; Mulsant, Benoit H.; Shinichiro Nakajima; Caravaggio, Fernando; Takefumi Suzuki; Hiroyuki Uchida; Gerretsen, Philip; Mar, Wanna; Pollock, Bruce G.; Mamo, David C. // JAMA Psychiatry;Sep2015, Vol. 72 Issue 9, p927 

    IMPORTANCE: Patients with late-life schizophrenia (LLS) are highly susceptible to antipsychotic adverse effects. Treatment guidelines endorse lower antipsychotic doses. However, the optimal dose of antipsychotics and associated dopamine D2/3 receptor (D2/3R) occupancies remain largely unexplored...

  • Schizophrenics' Improvement: Maybe It's the New Meds. Or Maybe Not.  // Behavior Analysis Digest International;Fall2010, Vol. 22 Issue 3, p12 

    The article discusses research on cognitive gains in schizophrenic patients given newer antipsychotic medications.

  • Novel Therapeutic Drugs for Neuropsychiatric Disorders. Hashimoto, Kenji // Open Medicinal Chemistry Journal;2010, Vol. 4, p1 

    The article discusses various reports published within the issue, including one by Sean Smith and colleagues on the therapeutic aspects of D-amino acid oxidase (DAAO), one by Akito Yasuhara and Shigeyuki Chaki on the therapeutic potential of Metabotropic glutamate receptors (mGluRs), and one by...

  • Atypical antipsychotic drugs. Mackin, Paul; Thomas, Simon H. L. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/19/2011, Vol. 342 Issue 7798, p650 

    The article discusses the use of antipsychotic drugs for the treatment of non-affective psychosis. It explores evidence on the efficacy of typical versus atypical antipsychotics. It mentions the adverse effects of atypical antipsychotics drugs including sedation, anticholinergic effects,...

  • Sertindole in the Management of Schizophrenia. Juruena, Mario F.; Pond de Sena, Eduardo; Reis de Oliveira, Irismar // Journal of Central Nervous System Disease;2011, Issue 3, p75 

    Nowadays, new schizophrenia treatments are more ambitious than ever, aiming not only to improve psychotic symptoms, but also quality of life and social reinsertion. Our objective is to briefly but critically review the diagnosis of schizophrenia, the atypical antipsychotics sertindole's...

  • Schizophrenia and other Psychotic Disorders.  // Current Medical Literature: Psychiatry;2010, Vol. 21 Issue 4, p123 

    The author comments on several articles about schizophrenia and other psychotic disorders. According to the author, the article by S. P. Singh et al. suggests that the combined antidepressants and antipsychotic medications are more effective compared to antipsychotics plus placebo in treating...

  • Psych Rx. FROM FDA FOR EXPANDED INDICATIONS FOR ATYPICAL ANTIPSYCHOTIC MEDICATION SAPHRIS (ASENAPINE) SUBLINGUAL TABLETS.  // Psychiatry (1550-5952);Sep2010, Vol. 7 Issue 9, p9 

    The article reports that the two supplemental drugs of Saphris sublingual tablets from Merck and Co. Inc. has been approved by the U.S. Food and Drug Administration (FDA).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics